Prime Medicine, Inc. Research and Development Expense
Prime Medicine, Inc. (PRME) reported Research and Development Expense of $33.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Prime Medicine, Inc. research and development expense for the quarter ending 2026-06-30 was $33.40M, a 19.28% decline year-over-year.
- Prime Medicine, Inc. research and development expense for the quarter ending 2026-03-31 was $34.10M, a 15.92% decline year-over-year.
- Prime Medicine, Inc. research and development expense for the quarter ending 2025-12-31 was $34.71M, a 1.77% increase year-over-year.
- Prime Medicine, Inc. research and development expense for the quarter ending 2025-09-30 was $43.99M, a 9.05% increase year-over-year.
- Prime Medicine, Inc. research and development expense for fiscal 2025 was $160.64M, a 3.44% increase from fiscal 2024.
- Prime Medicine, Inc. research and development expense for fiscal 2024 was $155.29M, a 4.99% increase from fiscal 2023.
- Prime Medicine, Inc. research and development expense for fiscal 2023 was $147.91M, a 70.54% increase from fiscal 2022.
- Prime Medicine, Inc. research and development expense for fiscal 2022 was $86.72M, a 22.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.40M 10-Q · filed 2026-08-06 | $67.50M 10-Q · filed 2026-08-06 | $102.21M derived: sum of 3 quarters · filed 2026-08-06 | $146.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $34.10M 10-Q · filed 2026-05-07 | $68.81M derived: sum of 2 quarters · filed 2026-05-07 | $112.80M derived: sum of 3 quarters · filed 2026-05-07 | $154.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $78.70M derived: sum of 2 quarters · filed 2026-03-03 | $120.07M derived: sum of 3 quarters · filed 2026-08-06 | $160.64M 10-K · filed 2026-03-03 |
| 2025-09-30 | $43.99M 10-Q · filed 2025-11-07 | $85.36M derived: sum of 2 quarters · filed 2026-08-06 | $125.93M 10-Q · filed 2025-11-07 | $160.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $41.38M 10-Q · filed 2026-08-06 | $81.94M 10-Q · filed 2026-08-06 | $116.04M derived: sum of 3 quarters · filed 2026-08-06 | $156.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $40.56M 10-Q · filed 2026-05-07 | $74.67M derived: sum of 2 quarters · filed 2026-05-07 | $115.01M derived: sum of 3 quarters · filed 2026-05-07 | $158.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $34.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $74.44M derived: sum of 2 quarters · filed 2026-03-03 | $117.52M derived: sum of 3 quarters · filed 2026-03-03 | $155.29M 10-K · filed 2026-03-03 |
| 2024-09-30 | $40.34M 10-Q · filed 2025-11-07 | $83.41M derived: sum of 2 quarters · filed 2025-11-07 | $121.19M 10-Q · filed 2025-11-07 | $162.64M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $43.07M 10-Q · filed 2025-08-07 | $80.84M 10-Q · filed 2025-08-07 | $122.30M derived: sum of 3 quarters · filed 2025-08-07 | $163.27M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $37.77M 10-Q · filed 2025-05-08 | $79.23M derived: sum of 2 quarters · filed 2025-05-08 | $120.20M derived: sum of 3 quarters · filed 2025-05-08 | $154.80M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $41.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $82.43M derived: sum of 2 quarters · filed 2025-02-28 | $117.03M derived: sum of 3 quarters · filed 2025-02-28 | $147.91M 10-K · filed 2025-02-28 |
| 2023-09-30 | $40.97M 10-Q · filed 2024-11-12 | $75.57M derived: sum of 2 quarters · filed 2024-11-12 | $106.45M 10-Q · filed 2024-11-12 | $135.51M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $34.60M 10-Q · filed 2024-08-08 | $65.48M 10-Q · filed 2024-08-08 | $94.54M derived: sum of 3 quarters · filed 2024-08-08 | $119.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $30.88M 10-Q · filed 2024-05-10 | $59.94M derived: sum of 2 quarters · filed 2024-05-10 | $84.99M derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $29.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $54.11M derived: sum of 2 quarters · filed 2024-03-01 | $86.72M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $25.05M 10-Q · filed 2022-11-14 | $57.66M 10-Q · filed 2022-11-14 | ||
| 2022-03-31 | $13.68M 10-Q · filed 2023-05-11 | $66.57M derived: sum of 2 quarters · filed 2023-05-11 | $73.97M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $52.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $60.29M derived: sum of 2 quarters · filed 2023-03-09 | $70.55M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $7.40M 10-Q · filed 2022-11-14 | $17.66M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $2.98M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |